Onconetix to Implement 1-for-5 Reverse Stock Split Effective March 25
Summary
Onconetix, Inc. announced a 1-for-5 reverse stock split, effective March 25, 2026, with its common stock beginning to trade on a split-adjusted basis at market open that day. This action follows the company's recent 10-K filing on March 13, which disclosed substantial doubt about its ability to continue as a going concern, and a PRE 14A filing on March 18, where shareholders approved the authority for such a split. The reverse split is a critical step intended to enable Onconetix to regain compliance with Nasdaq's $1.00 minimum bid price requirement, thereby avoiding potential delisting. While a necessary compliance measure, reverse splits often reflect underlying financial challenges, which are consistent with the company's previously disclosed going concern issues. Traders will be watching the stock's performance post-split and the company's ability to address its broader financial stability.
At the time of this announcement, ONCO was trading at $0.51 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $0.44 to $14.86. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.